MX2007005367A - Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca. - Google Patents
Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca.Info
- Publication number
- MX2007005367A MX2007005367A MX2007005367A MX2007005367A MX2007005367A MX 2007005367 A MX2007005367 A MX 2007005367A MX 2007005367 A MX2007005367 A MX 2007005367A MX 2007005367 A MX2007005367 A MX 2007005367A MX 2007005367 A MX2007005367 A MX 2007005367A
- Authority
- MX
- Mexico
- Prior art keywords
- remodeling
- ranolazine
- treatment
- heart failure
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a un metodo para revertir la remodelacion del ventriculo izquierdo mediante la administracion combinada de cantidades terapeuticamente efectivas de ranolazina y de por lo menos un agente de co-remodelacion, que puede ser un inhibidor de ACE, ARB, o un bloqueador-beta. El metodo encuentra utilidad en el tratamiento de la insuficiencia cardiaca. Esta invencion tambien se refiere a formulaciones farmaceuticas que son adecuadas para tal administracion combinada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62615404P | 2004-11-09 | 2004-11-09 | |
PCT/US2005/040824 WO2006053161A1 (en) | 2004-11-09 | 2005-11-09 | Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007005367A true MX2007005367A (es) | 2007-06-18 |
Family
ID=35892429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007005367A MX2007005367A (es) | 2004-11-09 | 2005-11-09 | Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca. |
Country Status (15)
Country | Link |
---|---|
US (2) | US20060111361A1 (es) |
EP (1) | EP1809289A1 (es) |
JP (1) | JP2008519770A (es) |
KR (1) | KR20070084063A (es) |
CN (1) | CN101072562A (es) |
AU (1) | AU2005304421A1 (es) |
BR (1) | BRPI0517650A (es) |
CA (1) | CA2586840A1 (es) |
IL (1) | IL183056A0 (es) |
MX (1) | MX2007005367A (es) |
NO (1) | NO20072934L (es) |
RU (1) | RU2007121707A (es) |
SG (1) | SG156681A1 (es) |
WO (1) | WO2006053161A1 (es) |
ZA (1) | ZA200703697B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040063717A1 (en) * | 2002-05-21 | 2004-04-01 | Andrew Wolff | Method of treating diabetes |
WO2008030581A1 (en) * | 2006-09-08 | 2008-03-13 | Symphony Medical, Inc. | Intramyocardial patterning for treating localized anomalies of the heart |
CA2670651A1 (en) * | 2006-12-21 | 2008-07-03 | Cv Therapeutics, Inc. | Reduction of cardiovascular symptoms |
EP2117549A1 (en) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
JP2010518181A (ja) * | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 心血管疾患の処置のためのラノラジンの使用 |
US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
WO2008101012A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of non-coronary microvascular diseases |
US20080233191A1 (en) * | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
WO2008127607A2 (en) * | 2007-04-11 | 2008-10-23 | Henry Ford Health System | Cardiac repair, resizing and reshaping using the venous system of the heart |
KR20100033490A (ko) * | 2007-05-31 | 2010-03-30 | 질레드 팔로 알토 인코포레이티드 | 상승된 뇌-형 나트륨이뇨 펩티드에 대한 라놀라진 |
WO2008154033A2 (en) * | 2007-06-11 | 2008-12-18 | Symphony Medical, Inc. | Cardiac patterning for improving diastolic function |
US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
JP2012526848A (ja) * | 2009-05-14 | 2012-11-01 | ギリアード サイエンシーズ, インコーポレイテッド | Cns障害の治療のためのラノラジン |
CA3130908A1 (en) | 2009-06-30 | 2010-12-30 | Mallinckrodt Hospital Products IP Limited | Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0714660B1 (en) * | 1989-06-23 | 2002-09-04 | Syntex (U.S.A.) LLC | Ranolazine and related piperazines for protecting skeletal muscles |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
US6323226B1 (en) * | 1999-10-19 | 2001-11-27 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
MXPA02007639A (es) * | 2000-02-18 | 2004-08-23 | Cv Therapeutics Inc | Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva. |
WO2002007716A2 (en) * | 2000-07-21 | 2002-01-31 | Cv Therapeutics, Inc. | Method for treating angina |
US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
-
2005
- 2005-11-09 AU AU2005304421A patent/AU2005304421A1/en not_active Abandoned
- 2005-11-09 US US11/271,168 patent/US20060111361A1/en not_active Abandoned
- 2005-11-09 WO PCT/US2005/040824 patent/WO2006053161A1/en active Application Filing
- 2005-11-09 CA CA002586840A patent/CA2586840A1/en not_active Abandoned
- 2005-11-09 KR KR1020077010435A patent/KR20070084063A/ko not_active Application Discontinuation
- 2005-11-09 CN CNA2005800380175A patent/CN101072562A/zh active Pending
- 2005-11-09 RU RU2007121707/14A patent/RU2007121707A/ru not_active Application Discontinuation
- 2005-11-09 BR BRPI0517650-6A patent/BRPI0517650A/pt not_active IP Right Cessation
- 2005-11-09 JP JP2007540416A patent/JP2008519770A/ja not_active Withdrawn
- 2005-11-09 SG SG200907097-0A patent/SG156681A1/en unknown
- 2005-11-09 MX MX2007005367A patent/MX2007005367A/es unknown
- 2005-11-09 EP EP05826116A patent/EP1809289A1/en not_active Withdrawn
-
2007
- 2007-05-08 IL IL183056A patent/IL183056A0/en unknown
- 2007-05-08 ZA ZA200703697A patent/ZA200703697B/xx unknown
- 2007-06-08 NO NO20072934A patent/NO20072934L/no not_active Application Discontinuation
-
2009
- 2009-02-26 US US12/393,952 patent/US20090176772A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2007121707A (ru) | 2008-12-20 |
ZA200703697B (en) | 2008-09-25 |
WO2006053161A1 (en) | 2006-05-18 |
KR20070084063A (ko) | 2007-08-24 |
BRPI0517650A (pt) | 2008-10-14 |
SG156681A1 (en) | 2009-11-26 |
US20090176772A1 (en) | 2009-07-09 |
JP2008519770A (ja) | 2008-06-12 |
IL183056A0 (en) | 2007-10-31 |
CN101072562A (zh) | 2007-11-14 |
US20060111361A1 (en) | 2006-05-25 |
AU2005304421A1 (en) | 2006-05-18 |
CA2586840A1 (en) | 2006-05-18 |
WO2006053161A8 (en) | 2006-09-14 |
NO20072934L (no) | 2007-08-08 |
EP1809289A1 (en) | 2007-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG156681A1 (en) | Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure | |
EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
WO2009137465A3 (en) | Compositions for treatment or prevention of pathological cardiac remodeling and heart failure | |
WO2004018419A3 (en) | Benzimidazole quinolinones and uses thereof | |
NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
NO20072654L (no) | Cancer behandling | |
IL174965A0 (en) | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE | |
ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
WO2004010937A3 (en) | Method of treating cancer | |
MX2007002311A (es) | Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos. | |
GB0018527D0 (en) | Composition | |
MY140514A (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
WO2005094554A3 (en) | Therapeutic agents, methods, and treatments | |
WO2008127594A3 (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
SG160425A1 (en) | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | |
ECSP11011030A (es) | Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional. | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
NO20054216L (no) | Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag | |
MA34547B1 (fr) | Traitement d'association pour traiter une infection par le vhc | |
AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
WO2020047352A8 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
MX2010010334A (es) | Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida. | |
WO2003092606A3 (en) | Cholinesterase inhibitors to prevent injuries caused by chemicals | |
MX2021003845A (es) | Composiciones para reducir el acido urico serico. |